Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited (AU:RAD)
ASX:RAD
RESEARCH TOOLSreports
Radiopharm Theranostics Limited (RAD) Share Price & Analysis
3 Followers
RAD Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.03 - AU$0.15
Previous CloseAU$0.04
Volume1.82M
Average Volume (3M)1.59M
Market Cap
AU$39.13M
Enterprise ValueAU$12.15M
Total Cash (Recent Filing)AU$26.98M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Sep 26, 2024EPS Estimate
-AU$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume1,587,051
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside1873.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Radiopharm Theranostics Limited News
PremiumCompany Announcements
Radiopharm Schedules EGM for Shareholder Engagement
PremiumCompany Announcements
Radiopharm Initiates Key NSCLC Clinical TrialPremiumCompany Announcements
Radiopharm Theranostics Shareholder Voting Power Diluted
PremiumCompany Announcements
Regal Funds Management Acquires Stake in Radiopharm
PremiumCompany Announcements
Point72 Discloses Major Stake in Radiopharm Theranostics
PremiumCompany Announcements
Radiopharm Theranostics Moves to Quote New Shares
PremiumCompany Announcements
Radiopharm Secures A$70M in Strategic Capital Raise
PremiumCompany Announcements
Radiopharm Theranostics Prepares for Capital RaiseBulls Say, Bears Say
Bulls Say
Clinical TrialsPhase I Australian trial of PD-L1-targeted Lu-177-based nanobody RAD204 in non-small cell lung cancer (NSCLC) is currently enrolling.
Pipeline DevelopmentPhase IIb IND preparations for lead F-18 imaging asset RAD101 in brain mets are ongoing with potential to initiate the trial in summer 2024.
ValuationGiven the progress across ASX:RAD's broad pipeline and continued momentum in the radiopharmaceutical field driven by high M&A activity and strong clinical and commercial results, the company is significantly undervalued.
Bears Say
Cash PositionThe cash position remains the most significant short-term risk to the company.
FinancingThe company ended 1Q24 with A$2.9M and will require additional funds to continue operations through 2024.
FundingPotential headwinds from a near-term financing overhang as the company ended 1Q24 with A$2.9M and will require additional funds to continue operations through 2024.
---
Options Prices
Currently, No data available
---
Ownership Overview
9.93% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
90.07% Public Companies and
Individual Investors
RAD FAQ
What was Radiopharm Theranostics Limited’s price range in the past 12 months?
Radiopharm Theranostics Limited lowest share price was AU$0.03 and its highest was AU$0.14 in the past 12 months.
What is Radiopharm Theranostics Limited’s market cap?
Currently, no data Available
When is Radiopharm Theranostics Limited’s upcoming earnings report date?
Radiopharm Theranostics Limited’s upcoming earnings report date is Sep 26, 2024 which is in 71 days.
How were Radiopharm Theranostics Limited’s earnings last quarter?
Radiopharm Theranostics Limited released its earnings results on Feb 29, 2024. The company reported -AU$0.072 earnings per share for the quarter, missing the consensus estimate of -AU$0.04 by -AU$0.032.
Is Radiopharm Theranostics Limited overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited’s price is currently Undervalued.
Does Radiopharm Theranostics Limited pay dividends?
Radiopharm Theranostics Limited does not currently pay dividends.
What is Radiopharm Theranostics Limited’s EPS estimate?
Radiopharm Theranostics Limited’s EPS estimate is -AU$0.04.
How many shares outstanding does Radiopharm Theranostics Limited have?
Radiopharm Theranostics Limited has 1,057,497,800 shares outstanding.
What happened to Radiopharm Theranostics Limited’s price movement after its last earnings report?
Radiopharm Theranostics Limited reported an EPS of -AU$0.072 in its last earnings report, missing expectations of -AU$0.04. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited?
Currently, no hedge funds are holding shares in AU:RAD
---
Radiopharm Theranostics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.75 (1873.68% Upside)
AU$0.75 (1873.68% Upside)
Blogger Sentiment
Neutral
AU:RAD Sentiment 58%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.25%
12-Months-Change
Fundamentals
Return on Equity
-108.75%
Trailing 12-Months
Asset Growth
-25.60%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited
Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
---
RAD Stock 12 Month Forecast
Average Price Target
AU$0.75
▲(1873.68% Upside)
Technical Analysis
Race Oncology Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Best Analysts Covering RAD
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-29.40%
reiterated a buy rating last month
Copying Justin Walsh's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -29.40% per trade.
---